238 related articles for article (PubMed ID: 28103976)
1. [Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].
Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):66-72. PubMed ID: 28103976
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
Iams WT; Lovly CM
Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
[TBL] [Abstract][Full Text] [Related]
3. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.
Vijayvergia N; Mehra R
Cancer Chemother Pharmacol; 2014 Sep; 74(3):437-46. PubMed ID: 25135623
[TBL] [Abstract][Full Text] [Related]
4. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
5. [Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].
Song P; Zhang L; Shang C
Zhongguo Fei Ai Za Zhi; 2018 Sep; 21(9):703-711. PubMed ID: 30201071
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.
Straughan DM; Azoury SC; Shukla V
Curr Drug Targets; 2016; 17(6):739-45. PubMed ID: 26073862
[TBL] [Abstract][Full Text] [Related]
8. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
10. [Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer].
Liu X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.
Shackelford RE; Ansari JM; Wei EX; Alexander JS; Cotelingam J
Pharmacogenomics; 2017 Aug; 18(12):1179-1192. PubMed ID: 28745554
[TBL] [Abstract][Full Text] [Related]
13. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
[TBL] [Abstract][Full Text] [Related]
14. Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.
Wang HY; Ho CC; Shih JY
J Thorac Oncol; 2017 May; 12(5):e49-e51. PubMed ID: 28434515
[No Abstract] [Full Text] [Related]
15. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
17. Molecular oncology of lung cancer.
Toyooka S; Mitsudomi T; Soh J; Aokage K; Yamane M; Oto T; Kiura K; Miyoshi S
Gen Thorac Cardiovasc Surg; 2011 Aug; 59(8):527-37. PubMed ID: 21850578
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for non-small-cell lung cancer: past, present and future.
Forde PM; Ettinger DS
Expert Rev Anticancer Ther; 2013 Jun; 13(6):745-58. PubMed ID: 23773106
[TBL] [Abstract][Full Text] [Related]
19. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
